For New Antipsychotic Users, Dose, Duration Impact Mortality

This article originally appeared here.
Share this content:
For New Antipsychotic Users, Dose, Duration Impact Mortality
For New Antipsychotic Users, Dose, Duration Impact Mortality

TUESDAY, May 17, 2016 (HealthDay News) -- Dose and duration of therapy are associated with mortality for new antipsychotic users, according to a study published online May 10 in the Journal of the American Geriatrics Society.

Linda Simoni-Wastila, Ph.D., from the University of Maryland in Baltimore, and colleagues conducted a retrospective cohort study of Medicare beneficiaries who had a Minimum Data Set 2.0 clinical assessment completed between 2007 and 2009. The authors identified three mutually exclusive cohorts of new antipsychotic users with evidence of severe mental illness (SMI; 5,621 participants); dementia with behavioral symptoms (dementia + behavior) without SMI (1,090 participants); or delirium without SMI or dementia + behavior (2,100 participants). The dose (modified standardized daily dose [mSDD]) and duration of therapy with antipsychotic were assessed monthly.

The researchers found that mortality risk was significantly lower for new antipsychotic users with a mSDD of ≤1 versus those with a mSDD >1 (hazard ratio [HR]SMI, 0.77; HRdementia + behavior, 0.52; and HRdelirium, 0.61, respectively). Significantly lower mortality was seen with longer duration of antipsychotic use (91 to 184 days for SMI and delirium) versus short duration of use (≤30 days for SMI; ≤7 days for delirium). In the SMI cohort, the interaction between dose and duration was statistically significant (P < 0.001).

"Prescribers should monitor antipsychotic dosage throughout the course of antipsychotic treatment and customize dose and duration regimens to an individual's indications," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Seeks to Increase Number of Generic Drugs on Market

FDA Seeks to Increase Number of Generic Drugs ...

Agency will now give priority reviews to new generic drugs until there are at least three available

PPIs Not Found to Raise Risk of Alzheimer's Disease

PPIs Not Found to Raise Risk of Alzheimer's ...

New research debunks other studies suggesting that PPIs cause mental decline

Aspirin Effective in Pregnancies at High Risk for Preeclampsia

Aspirin Effective in Pregnancies at High Risk for ...

Odds of preeclampsia drop for high-risk women who take 150 mg of aspirin daily, researchers find

is free, fast, and customized just for you!

Already a member?

Sign In Now »